John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive


Hepatitis B virus reactivation in patients with digestive tract tumours receiving systemic anti-cancer treatment Volume 24, issue 7, Septembre 2017


1 Hôpital Cochin, service de gastro-entérologie, d’endoscopie et d’oncologie digestive, 27 rue du faubourg St Jacques, 75014 Paris, France ; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
2 Hôpital Cochin, service d’hépatologie ; Université Paris Descartes, Sorbonne Paris Cité, Paris, France ; Inserm U1223 et USM20, Institut Pasteur, Paris, France.
* Tirés à part

Patients treated with chemotherapy for haematological disease have a known risk of reactivation of hepatitis B virus (HBV) with an estimated incidence of 14-72%. Conversely, very little data exist on viral B reactivation in patients receiving chemotherapy for a digestive malignancy.

In this review, a search of the literature data was carried out in an attempt to evaluate the risk of reactivation of HBV during treatment for a digestive malignancy. Based on these data, a ranking of the risk of HBV reactivation and recommendations for the most commonly used anticancer drugs in solid tumors was performed.

The majority of anti-cancer drugs can in patients with HBs-positive antigen induce reactivation of HBV. Screening for HBs antigen should be recommended before chemotherapy. Thus, preventive antiviral therapy can therefore reduce the risk of reactivation of HBV.